Chemistry:List of adverse effects of valproate semisodium
From HandWiki
Short description: None
Adverse effects by frequency for use of valproate semisodium.[1][2][3]
Very common (>10% frequency)
- Nausea
- Tremor
Common (1-10% frequency)
- Liver injury
- Gastralgia
- Diarrhoea
- Extrapyramidal (movement) disorder
- Stupor[lower-alpha 1]
- Somnolence
- Convulsion[lower-alpha 1]
- Memory impairment
- Headache
- Nystagmus
- Confusional state
- Aggression[lower-alpha 2]
- Agitation[lower-alpha 2]
- Impaired attention[lower-alpha 2]
- Hyponatraemia
- Anaemia
- Thrombocytopaenia
- Hypersensitivity
- Transient and/or dose-related hair loss
- Dysmenorrhea
- Haemorrhage (bleeding)
- Weight gain[lower-alpha 3]
Uncommon (0.01-0.1% frequency)
- Pancreatitis (sometimes lethal)
- Coma[lower-alpha 1]
- Lethargy[lower-alpha 1]
- SIADH
- Pancytopenia
- Leucopenia
- Rash
- Angioedema
- Amenorrhoea (absence of menstrual cycle)
- Vasculitis
- Peripheral oedema
- Reduced bone mineral density
- Osteopaenia
- Osteoporosis
- Pleural effusions
- Gingival enlargement
- Phasmophobia
Rare (<0.01% frequency)
- Reversible dementia
- Reversible cerebral atrophy
- Abnormal behaviour[lower-alpha 2]
- Psychomotor hyperactivity[lower-alpha 2]
- Learning disorder[lower-alpha 2]
- Hyperammonaemia
- Hypothyroidism
- Bone marrow failure
- Toxic epidermal necrolysis
- Stevens–Johnson syndrome
- Erythema multiforme
- DRESS syndrome
- Male infertility
- Polycystic ovaries
- Enuresis
- Reversible Fanconi syndrome
- Coagulation abnormalities
- Systemic lupus erythematosus
- Gynaecomastia
Notes
- ↑ 1.0 1.1 1.2 1.3 Rare cases of lethargy occasionally progressing to stupor, sometimes with associated hallucinations or convulsions have been reported. Encephalopathy and coma have very rarely been observed. These cases are most often seen in association with other factors such as rapid dose escalations or withdrawal from other medications. They have usually been reversible on withdrawal of treatment or reduction of dosage.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 These cases most commonly occur in the paediatric population.
- ↑ Weight gain should be monitored closely as there is a potential link between weight gain and polycystic ovary syndrome.
References
- ↑ "Depakote 250mg Tablets - Summary of Product Characteristics". electronic Medicines Compendium. Sanofi. 28 November 2013. http://www.medicines.org.uk/emc/medicine/25929/SPC/Depakote+250mg+Tablets/.
- ↑ "DEPAKOTE (divalproex sodium) tablet, delayed release [AbbVie Inc."]. DailyMed. AbbVie Inc.. September 2013. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=08a65cf4-7749-4ceb-6895-8f4805e2b01f.
- ↑ "Depakote (divalproex sodium) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. http://reference.medscape.com/drug/depakote-divalproex-sodium-999832#showall.
 |  |
